Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Aziyo Biologics, Inc. (AZYO)

    Price:

    1.49 USD

    ( + 0.03 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    AZYO
    Name
    Aziyo Biologics, Inc.
    Industry
    Medical - Devices
    Sector
    Healthcare
    Price
    1.490
    Market Cap
    24.212M
    Enterprise value
    57.396M
    Currency
    USD
    Ceo
    C. Randal Mills
    Full Time Employees
    151
    Website
    Ipo Date
    2020-10-08
    City
    Silver Spring
    Address
    12510 Prosperity Drive

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Abiomed, Inc.

    VALUE SCORE:

    0

    Symbol
    ABMD
    Market Cap
    17.181B
    Industry
    Medical - Devices
    Sector
    Healthcare

    2nd position

    PROCEPT BioRobotics Corporation

    VALUE SCORE:

    9

    Symbol
    PRCT
    Market Cap
    2.199B
    Industry
    Medical - Devices
    Sector
    Healthcare

    The best

    Viemed Healthcare, Inc.

    VALUE SCORE:

    11

    Symbol
    VMD
    Market Cap
    266.959M
    Industry
    Medical - Devices
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -4.155
    P/S
    3.795
    P/B
    -2.117
    Debt/Equity
    -0.675
    EV/FCF
    -3.295
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    4.629
    Earnings yield
    -0.241
    Debt/assets
    0.834
    FUNDAMENTALS
    Net debt/ebidta
    -1.410
    Interest coverage
    -9.589
    Research And Developement To Revenue
    0.168
    Intangile to total assets
    0.194
    Capex to operating cash flow
    -0.014
    Capex to revenue
    0.020
    Capex to depreciation
    0.136
    Return on tangible assets
    -0.782
    Debt to market cap
    0.314
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    -0.024
    P/CF
    -1.762
    P/FCF
    -0.691
    RoA %
    -112.508
    RoIC %
    -65.185k
    Gross Profit Margin %
    67.172
    Quick Ratio
    0.449
    Current Ratio
    0.587
    Net Profit Margin %
    -290.333
    Net-Net
    -1.412
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.796
    Revenue per share
    0.567
    Net income per share
    -0.510
    Operating cash flow per share
    -0.785
    Free cash flow per share
    -0.796
    Cash per share
    0.203
    Book value per share
    -1.001
    Tangible book value per share
    -1.159
    Shareholders equity per share
    -1.001
    Interest debt per share
    0.767
    TECHNICAL
    52 weeks high
    9.010
    52 weeks low
    1.100
    Current trading session High
    1.540
    Current trading session Low
    1.400
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.899
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.899
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.984
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -105.336
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.137
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -152.771
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.642
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    23.204
    logo

    Country
    CR
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -13.091
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    -2.688405%
    P/E
    -0.000

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.900
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.039
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.059
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.279
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.647
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.293
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -29.774
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.022

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.181
    DESCRIPTION

    Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

    NEWS
    https://images.financialmodelingprep.com/news/elutia-to-present-at-the-hc-wainwright-25th-annual-20230908.jpg
    Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    globenewswire.com

    2023-09-08 08:30:00

    SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.

    https://images.financialmodelingprep.com/news/aziyo-biologics-announces-publication-of-a-cangaroo-case-study-20230830.jpg
    Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

    globenewswire.com

    2023-08-30 08:30:00

    Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-q2-2023-earnings-call-transcript-20230820.jpg
    Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript

    seekingalpha.com

    2023-08-20 12:41:05

    Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call.

    https://images.financialmodelingprep.com/news/aziyo-biologics-reports-second-quarter-2023-financial-results-transformation-20230814.jpg
    Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

    globenewswire.com

    2023-08-14 16:05:00

    Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

    https://images.financialmodelingprep.com/news/aziyo-biologics-to-report-second-quarter-2023-financial-results-on-20230731.jpg
    Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

    globenewswire.com

    2023-07-31 16:05:00

    SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

    https://images.financialmodelingprep.com/news/aziyo-biologics-announces-voluntary-recall-of-viable-bone-matrix-20230713.jpg
    Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products

    globenewswire.com

    2023-07-13 16:30:00

    SILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-q1-2023-earnings-call-transcript-20230514.jpg
    Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript

    seekingalpha.com

    2023-05-14 21:32:09

    Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call.

    https://images.financialmodelingprep.com/news/aziyo-biologics-to-report-first-quarter-2023-financial-results-20230503.jpg
    Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

    globenewswire.com

    2023-05-03 16:05:00

    SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-could-find-a-support-soon-20230405.jpg
    Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

    zacks.com

    2023-04-05 11:26:30

    Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-q4-2022-earnings-call-transcript-20230322.jpg
    Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript

    seekingalpha.com

    2023-03-22 18:12:04

    Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

    https://images.financialmodelingprep.com/news/acers-stock-down-on-failure-of-phase-ii-study-20230320.jpg
    ACER's Stock Down on Failure of Phase II Study, Cash Updates

    zacks.com

    2023-03-20 13:46:12

    ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

    https://images.financialmodelingprep.com/news/aziyo-biologics-to-report-fourth-quarter-and-full-year-20230315.jpg
    Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023

    globenewswire.com

    2023-03-15 16:05:00

    SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

    https://images.financialmodelingprep.com/news/aziyo-biologics-to-present-at-the-cowen-43rd-annual-20230227.jpg
    Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference

    globenewswire.com

    2023-02-27 08:15:00

    SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-upgraded-to-buy-heres-what-you-20230126.jpg
    Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know

    zacks.com

    2023-01-26 13:33:27

    Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    https://images.financialmodelingprep.com/news/aziyo-biologics-to-participate-in-upcoming-investor-conferences-20221121.jpg
    Aziyo Biologics to Participate in Upcoming Investor Conferences

    globenewswire.com

    2022-11-21 16:05:00

    SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:

    https://images.financialmodelingprep.com/news/aziyo-biologics-inc-azyo-q3-2022-earnings-call-transcript-20221115.jpg
    Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript

    seekingalpha.com

    2022-11-15 16:38:11

    Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call.